Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) and QuidelOrtho (NASDAQ:QDEL – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.
Valuation & Earnings
This table compares Oruka Therapeutics and QuidelOrtho”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oruka Therapeutics | N/A | N/A | -$5.34 million | ($6.26) | -3.24 |
| QuidelOrtho | $3.00 billion | 0.92 | -$10.10 million | ($27.90) | -1.47 |
Oruka Therapeutics has higher earnings, but lower revenue than QuidelOrtho. Oruka Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Profitability
This table compares Oruka Therapeutics and QuidelOrtho’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oruka Therapeutics | N/A | -24.96% | -21.22% |
| QuidelOrtho | -66.25% | 4.24% | 2.17% |
Analyst Ratings
This is a summary of current ratings and price targets for Oruka Therapeutics and QuidelOrtho, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oruka Therapeutics | 0 | 0 | 7 | 1 | 3.13 |
| QuidelOrtho | 1 | 3 | 3 | 0 | 2.29 |
Oruka Therapeutics currently has a consensus target price of $43.17, indicating a potential upside of 113.06%. QuidelOrtho has a consensus target price of $58.83, indicating a potential upside of 43.08%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Oruka Therapeutics is more favorable than QuidelOrtho.
Institutional & Insider Ownership
56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Comparatively, 1.0% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Oruka Therapeutics beats QuidelOrtho on 9 of the 14 factors compared between the two stocks.
About Oruka Therapeutics
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.
About QuidelOrtho
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
